Neuromuscular

Biohaven’s verdiperstat has entered a phase 3 trial for the treatment of multiple system atrophy, with a new drug application submission on the agenda for late 2021.

The sBLA for onabotulinumtoxinA is supported by the findings from a randomized, double-blind phase 3 study evaluating the safety and efficacy of onabotulinumtoxinA in more than 100 pediatric patients.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

Preliminary results showed that SRP-9001 is associated with clinically meaningful improvement that is greater than that observed with standard-of-care treatment, including corticosteroids.

The data, from the phase 3 COMET trial, will be the basis for global regulatory submissions in the second half of 2020, according to manufacturer Sanofi.

Neurology News Network for the week ending June 20, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

The new data from the phase 2 NURTURE study are set to be presented at the virtual Cure SMA Research and Clinical Care Meeting.

The funding for the Pediatric Neuromuscular Clinical Research Network will provide assistance to some of the world's highly skilled clinical trial investigators who have led studies that have resulted in numerous FDA approvals of breakthrough treatments.

Data show the therapy’s positive safety and expression results from a small number of clinical trial participants with limb-girdle muscular dystrophy type 2E out to 1 year.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

The consultant for the Muscular Dystrophy Association’s Chief Medical Advisory Team and associate professor of neurology at Columbia University offered his perspective on some of the latest news in ALS.

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital details his personal responsibilities and the long-term goals for the new center.

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute detailed his experience managing patients with various conditions through a telemedicine platform.

Neurology News Network for the week ending May 23, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

Cure SMA joins the list of influential and impactful organizations within the Strategic Alliance Program.

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute discussed the institute’s transition to telemedicine and how it has been utilized.

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital gives an overview on what neurologic disorders the new center will focus on.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.